

JPET#82487

## Title page

# Role of TRPV1 receptors in adjuvant-induced chronic arthritis: *in vivo* study using gene-deficient mice

Árpád Szabó, Zsuzsanna Helyes, Katalin Sándor, Andrea Bite, Erika Pintér, József  
Németh, Ágnes Bánvölgyi, Kata Bölcskei, Krisztián Elekes and  
János Szolcsányi

Department of Pharmacology and Pharmacotherapy, Faculty of Medicine (Á.Sz., Zs.H., K.S.,  
A.B., E.P., Á.B., K.B., K.E., J.Sz.), University of Pécs

Neuropharmacological Research Group of the Hungarian Academy of Sciences, (J.N., J.Sz.)

H-7643, Pécs, Szigeti u. 12. Hungary

JPET#82487

## Running Title Page

### Running title: Role of TRPV1 in adjuvant-induced chronic murine arthritis

Corresponding author: János Szolcsányi, M.D., Ph.D., D.Sc.

Department of Pharmacology and Pharmacotherapy,

University of Pécs,

*Pécs-7624, Szigeti u. 12., Hungary*

**Tel.: 36-72-536001/ 5386, 5591; Fax.: 36-72-536218**

*e-mail:* [janos.szolcsanyi@aok.pte.hu](mailto:janos.szolcsanyi@aok.pte.hu)

Number of text pages: 27

Number of tables: 0

Number of figures: 6

Number of references: 40

Number of words in the Abstract: 247

Number of words in the Introduction: 701

Number of words in the Discussion: 1188

Nonstandard abbreviations: CFA = Complete Freund's adjuvant; TRPV1 = transient receptor potential vanilloid 1; NDGA = nordihydroguaretic acid

Recommended section: Inflammation and Immunopharmacology

JPET#82487

## Abstract

The transient receptor potential vanilloid 1 (TRPV1) receptor is a non-selective cation channel localized on a subset of primary sensory neurons and can be activated by a wide range of stimuli. The present study investigated the role of this receptor in chronic arthritis evoked by complete Freund's adjuvant (CFA) using TRPV1 receptor gene-deleted (TRPV1<sup>-/-</sup>) mice and wild-type counterparts (TRPV1<sup>+/+</sup>). In TRPV1<sup>+/+</sup> mice CFA injected intraplantarly into the left hindpaw and the root of the tail induced swelling of the injected and contralateral paws up to 130% and 28%, respectively, measured by plethysmometry throughout 18 days. Mechanonociceptive threshold measured with dynamic plantar aesthesiometry was decreased by 50% and 18% on the injected and contralateral paws, respectively. Histological examination and scoring of the tibiotarsal joints revealed marked arthritic changes in wild-type mice. In TRPV1<sup>-/-</sup> animals oedema, histological score and mechanical allodynia were significantly smaller. Daily treatment with the lipoxigenase inhibitor nordihydroguaric acid (NDGA), the cyclooxygenase inhibitor indomethacin, the bradykinin B2 receptor antagonist HOE-140 or the B1 receptor antagonist desArgHOE-140 was performed to reveal what mediators might activate TRPV1. NDGA significantly inhibited oedema, hyperalgesia and arthritis score in TRPV1<sup>+/+</sup>, but not or in TRPV1<sup>-/-</sup> mice. The effect of indomethacin was markedly smaller in knockouts. In TRPV1<sup>+/+</sup> animals HOE-140, but not desArgHOE-140 inhibited arthritis, while in TRPV1<sup>-/-</sup> mice HOE-140 produced limited effect. Thus, whereas bradykinin and lipoxigenase products seem to act exclusively via TRPV1 activation, prostanoids do not, or at least only partially to enhance murine experimental arthritis and related hyperalgesia.

## Introduction

The transient receptor potential vanilloid (TRPV) subfamily of TRP cation channels consists of at least six members of membrane proteins in mammalian cells. The first representative of this family (TRPV1) was discovered by a systemic search for the postulated capsaicin receptor (Szolcsanyi 1993). The TRPV1 cation channel, which was formerly called vanilloid receptor 1 (VR1), is expressed in a major group of nociceptive primary afferent neurons (Caterina et al., 1997) and gated by noxious heat, protons (Caterina et al., 1997; Tominaga et al., 1998), endogenous lipids like anandamide (Gauldie et al., 2001), oleoyldopamine (Chu et al., 2003), N-arachidonoyldopamine (Huang et al., 2002), arachidonyl-2-chloroethylamide (Baker and McDougall, 2004) and lipoxygenase products like 12-(S)-hydroxyperoxyeicosatetraenic acid (12-(S)-HPETE) (Hwang et al., 2000). Vanilloid compounds like the plant-derived natural irritants, capsaicin and resiniferatoxin (RTX), activate only the TRPV1 channel members of the TRPV family. Consequently, the effects of capsaicin tested so far *in vivo* or *in vitro* were absent in TRPV1 gene-deleted mice (Caterina et al., 2000; Davis et al., 2000). On the other hand, more and more data indicate that further endogenous mediators of pain and inflammation also stimulate the nociceptive endings partially by gating the TRPV1 cation channels through intracellular pathways (Garcia-Martinez et al., 2002). TRPV1 is now considered as an integrator target molecule for a variety of noxious stimuli (Tominaga et al., 1998). This conclusion is in accordance with early observation on capsaicin pretreated (desensitised) rats, since in these animals the characteristic feature is the selective analgesia to chemonociceptive stimuli (Szolcsanyi, 1993).

Several results indicate that sensory innervation of the joint by capsaicin-sensitive, TRPV1-expressing primary afferent neurons is not only involved in sensory input for stretch and



JPET#82487

pain, but these nerve fibres also exert local and systemic effector functions (Maggi, 1995; Szolcsanyi, 1996). Neuropeptides released from these fibres into the surrounding tissues elicit neurogenic inflammation around the site of activation. Calcitonin gene-related peptide (CGRP) induces local vasodilatation and tachykinins, like substance P (SP) evoke plasma protein extravasation in the innervated area (Maggi, 1995; Szolcsanyi, 1996). Furthermore, they have trophic role and they cooperate with the immune system (Ferrell and Lam, 1996). SP releases inflammatory mediators from mast cells, induces the secretion of PGE<sub>2</sub> and collagenase from synoviocytes and IL-1 from macrophages (Lam and Ferrell, 1991). These mechanisms are also implicated in chronic inflammatory reactions, like rheumatoid arthritis (Jorgensen and Sany, 1994), which is a major problem in medicine. Arthritic joint characteristically displays hyperplasia of the synovial tissue contributing to pannus formation, mononuclear cell infiltration, destruction of cartilage and subchondral bone. Spontaneous pain and allodynia elicited by activation and/or sensitization of nociceptors by inflammatory mediators like bradykinin, lipoxigenase enzyme products, prostaglandins and protons are also predominant symptoms of all forms of human arthritic diseases. Increased level of pro-inflammatory sensory neuropeptides has been demonstrated in the synovial fluid taken from patients with rheumatoid arthritis (Marabini et al., 1991) and also from arthritic experimental animals (Bileviciute et al., 1993). It is suggested, that SP and CGRP constitute the most important group of neurogenic mediators of the inflammatory process and also participate in the nociceptive pathway.

Participation of the TRPV1 receptor in acute inflammatory and nociceptive models has been investigated. In TRPV1-null mutant mice neurogenic inflammation induced by mustard oil (Banvolgyi et al., 2004), oedema evoked by carrageenin or mechanical hyperalgesia one day after the injection of complete Freund's adjuvant into the hindpaw were similar to the TRPV1<sup>+/+</sup> controls (Caterina et al., 2000). On the other hand, hyperalgesia to noxious heat in these acute

JPET#82487

inflammatory conditions were markedly inhibited or abolished in the TRPV1 receptor knockout mice (Davis et al., 2000). However, there are no data on the role of this receptor under long-term inflammatory conditions.

Therefore, the aim of the present study was to adapt adjuvant-induced arthritis originally developed in Lewis rats to mice and analyse the development of chronic inflammation and related mechanical hyperalgesia in animals lacking the TRPV1 receptor. Further experiments were designed to reveal the role of cyclooxygenase/lipoxygenase enzyme products and bradykinin in the activation or sensitization of the TRPV1 receptor in the present model using enzyme inhibitors and receptor antagonists. It was intended to shed light on the participation of TRPV1 in the effects of inflammatory mediators released during long-term systemic arthritis.

JPET#82487

## Methods

### Animals

Experiments were performed on male TRPV1 receptor gene knockout mice (TRPV1<sup>-/-</sup>) and their wild-type counterparts (TRPV1<sup>+/+</sup>) weighing 20-25 g. Two breeding pairs of TRPV1<sup>+/-</sup> heterozygote mice were given as generous gifts from Dr. J.B. Davis (GlaxoSmithKline, Harlow, U.K.). The genotype of the animals in the first generation was determined by Southern blot analysis and PCR. The TRPV1<sup>+/+</sup> and TRPV1<sup>-/-</sup> were successfully bred on as wild-type and knockout mice in the Laboratory Animal Centre of the University of Pécs under standard pathogen free conditions at 24-25 °C provided with standard chow and water *ad libitum*, from where they were obtained for the experiments.

### Generation of TRPV1 receptor knockout mice

The generation of TRPV1 receptor knockout mice was by homologous recombination in embryonic stem cells (129 ES) to generate a mouse lacking transmembrane domains 2-4 of the mTRPV1 gene. Germline chimaeras were crossed onto C57BL/6 females to generate heterozygotes, which were inter-crossed giving rise to healthy homozygous mutant offsprings in the expected Mendelian ratio, as described by Davis and co-workers (Davis et al., 2000). After genotyping by PCR, they were bred from homozygous knockout breeding pairs, so all offsprings were also homozygous knockouts (TRPV1<sup>-/-</sup>), as described.

### Induction of arthritis

Arthritis of the left tibio-tarsal joint of the mice (20-25 g; n=8-12) was evoked by s.c. injection of complete Freund's adjuvant (CFA; killed Mycobacteria suspended in paraffin oil; 0.05 ml, 1

JPET#82487

mg/ml) into the plantar surface of the left hindpaw and the root of the tail. In order to enhance systemic effects, an additional injection was given into the tail on the following day (Helyes et al., 2004).

### **Measurement of paw oedema and mechanonociceptive threshold**

The volume of the paws was measured by plethysmometry (Ugo Basile Plethysmometer 7140, Comerio, Italy) and the mechanical touch sensitivity of the paws by aesthesiometry (Ugo Basile Dynamic Plantar Aesthesiometer 37400, Comerio, Italy) before the experiment and 2, 5, 8, 12, 15, 18 and 21 days after CFA administration.

The plethysmometer consists of two vertical interconnected water-filled Perspex cells, the larger of which is used to measure volume displacement induced by immersion of the mouse paw. The water level in an interconnected smaller tube, which contains a force transducer, generates a proportional volume measurement of the mouse paw which is expressed in cm<sup>3</sup>.

The aesthesiometer is used to assess touch sensitivity on the plantar surface of the paw. The mice move about freely in one of the two compartments of the enclosure positioned on the metal mesh surface. Following acclimation after cessation of exploratory behaviour, the operator places the touch stimulator unit under the animal's paw, using the adjustable angled-mirror to position the filament below the target area of the paw. After pressing the "start" key an electrodynamic actuator of proprietary design lifts a straight metal filament, which touches the plantar surface and begins to exert an increasing upward force at a preset rate of application until a stop signal (when the animal removes the paw) is attained. The paw withdrawal threshold is numerically shown in grams on the digital screen. Oedema and hyperalgesia were expressed as percentage of initial control values.

JPET#82487

## **Histological processing**

The left tibiotarsal joints were excised after killing the animals by Nembutal (pentobarbital sodium) overdose (100 mg/kg i.p.) on the 21<sup>st</sup> day after CFA administration. The specimens were fixed in 4% formaldehyde for 8 h, decalcified in a demineralizing solution containing 7 w/v% AlCl<sub>3</sub>, 5 v/v% formic acid and 8.5 v/v% HCl for 8 h at 4 °C (Helyes et al., 2004). Non-inflamed joints decalcified paralelly at the same time were used as control samples to make sure that the decalcination procedure was appropriate. Once the joints had become sufficiently soft, they were washed in Sörensen phosphate buffer. They were dehydrated at 4 °C for 8 h in 5 w/v% in saccharose followed by immersion into 10 and 15 w/v% saccharose for subsequent two periods of 8 h. Then the samples were embedded in paraffin, sectioned with microtome (5 µm) and stained with hematoxylin and eosin.

## **Assessment of joint inflammation**

Arthritic changes were scored by an observer blinded to the treatment the animals received using a grading scale of 0-3 according to the proportion of areolar tissue that was densely infiltrated with mononuclear cells. Synovial lining cell hyperplasia and the number of leukocytes observed in the synovial tissue were graded similarly on the same scale. Cartilage destruction was scored on a scale of 0-3, ranging from no damage to fully destroyed cartilage layers. Bone erosion scores were obtained for the following features: 0= normal, 1= mild loss of cortical bone at a few sites, 2= moderate loss of cortical trabecular bone, 3= marked loss of bone at many sites. The score values given for these four different histopathological features were added to generate a composite arthritis score ranging between 0 and 12 (Helyes et al., 2004). From every joint (6-8 mice in each group) 4-5 sections were taken from different depths to give a representative

JPET#82487

appreciation of the whole joint. Mean scores were determined from the different sections of the individual animals and composite score values of the different experimental groups were calculated from these mean scores.

## **Drug treatments**

For examining the role of lipoxygenase products in the activation of TRPV1 receptors under long-term inflammatory conditions, one group of animals was treated every day throughout the whole 18-day-period with nordihydroguaretic acid (NDGA; 25 mg/kg i.p.; Chacur et al., 2001), a non-selective lipoxygenase inhibitor. In the second group, the bradykinin B1 receptor antagonist desArgHOE-140 (250 µg/kg i.p.; Ferreira et al., 2001), in the third one the B2 receptor antagonist HOE-140 (250 µg/kg i.p.; Wirth et al., 1991) was administered daily. Mice in the fourth group received daily treatment of indomethacin (1 mg/kg i.p.; Gauldie et al, 2004), the non-selective cyclooxygenase enzyme inhibitor. There were 6-12 animals in each experimental group.

## **Ethics**

All experimental procedures were carried out according to the 1998/XXVIII Act of the Hungarian Parliament on Animal Protection and Consideration Decree of Scientific Procedures of Animal Experiments (243/1988) and complied with the recommendations of the International Association for the Study of Pain and the Helsinki Declaration. The studies were approved by the Ethics Committee on Animal Research of Pécs University according to the Ethical Codex of Animal Experiments and licence was given (licence No.: BA 02/200-6-2001).

JPET#82487

## Statistical analysis

For determining statistically significant differences between the results of paw oedema and hyperalgesia measurements of different groups, analysis of variance (two-way ANOVA) followed by Bonferroni's modified t-test was used. Analysis of the composite arthritis score was performed by non-parametric Mann-Whitney U-test. In both cases  $p < 0.05$  was considered significant.

## Drugs and chemicals

Complete Freund's adjuvant, desArgHOE-140 (D-Arginyl-L-Arginyl-L-Prolyl-trans-4-Hydroxy-L-Prolyl-glycyl-3-(2-Thienyl)-L-Alanyl-L-Seryl-D-1,2,2,4-Tetrahydro-3-Isoquinolinecarbonyl-L-(2a,3b,7ab)-Octahydro-1H-Indole-2-Carbonyl), HOE-140 (D-Arginyl-L-Arginyl-L-Prolyl-trans-4-Hydroxy-L-Prolyl-glycyl-3-(2-Thienyl)-L-Alanyl-L-Seryl-D-1,2,2,4-Tetrahydro-3-Isoquinolinecarbonyl-L-(2a,3b,7ab)-Octahydro-1H-Indole-2-Carbonyl-L-Arginine), nordihydroguaretic acid (NDGA; 1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane) and indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid) were purchased from Sigma (St. Louis, MO, U.S.A.), pentobarbital sodium (Nembutal) from Serva (Heidelberg, Germany). Indomethacin was dissolved in 5%  $\text{NaHCO}_3$  and diluted with sterile saline. Stock solution of desArgHOE-140, HOE-140 and NDGA were made with 96% ethanol. The final solution contained 10% of this stock solution, 5% Tween 80 and 85% isotonic saline.

## Results

The weights of the animals remained unchanged over the period of the study with no significant differences between the TRPV1<sup>+/+</sup> and TRPV1<sup>-/-</sup> groups.

### **CFA-induced paw oedema, mechanical hyperalgesia and arthritic histological changes in TRPV1<sup>+/+</sup> and TRPV1<sup>-/-</sup> mice**

One day after CFA injection, neither oedema (TRPV1<sup>+/+</sup>: 46.38±4.22% and TRPV1<sup>-/-</sup>: 36.69±3.91%; p=0.06), nor mechanical hyperalgesia (TRPV1<sup>+/+</sup>: 31.24±4.52% and TRPV1<sup>-/-</sup>: 26.86±3.68; p=0.18) differed significantly in the two groups. In TRPV1<sup>+/+</sup> mice the volume of the CFA-injected paw gradually increased reaching a maximal swelling of 130% 16 days after the induction of inflammation, while 30% oedema developed on the contralateral paw. In TRPV1<sup>-/-</sup> mice oedema of both the CFA-treated and the contralateral paws was significantly smaller, with a maximum of 80% and 15%, respectively, throughout the 18-day-experimental period (p<0.05, two-way ANOVA; Figure 1). In TRPV1<sup>+/+</sup> animals mechanical touch sensitivity threshold of the CFA-treated paws decreased by 45-50% and on the contralateral paw 10-15% hyperalgesia developed. Meanwhile, in TRPV1<sup>-/-</sup> mice mechanonociceptive threshold drop of the CFA-treated paw was only 30-35% and no hyperalgesia developed on the contralateral side (p<0.05, two-way ANOVA; Figure 2).

Compared to the normal joint structure (Fig. 3a), the left tibio-tarsal joints of CFA-treated TRPV1<sup>+/+</sup> mice were damaged by expanding synovial pannus. Widening of the synovial cavity, mononuclear cell infiltration, thickening of the synovial membrane, disruption of the cartilaginous tissue and massive bone damage were apparent (Figure 3b). Joint samples of



JPET#82487

TRPV1<sup>-/-</sup> mice showed moderate inflammatory changes, there was small cartilage erosion, bone damage was not seen, enlargement and mononuclear cell infiltration of the synovial tissue was less pronounced than in TRPV1<sup>+/+</sup> animals (Figure 3c,d). There was no prominent difference between the additive scores given for synovial swelling/cellular infiltration, it was  $4.57 \pm 0.67$  in the TRPV1<sup>+/+</sup> and  $3.17 \pm 0.88$  in the TRPV1<sup>-/-</sup> group. On the other hand, cartilage/bone destruction was minimal in mice lacking the TRPV1 receptor, the scores for these two parameters were  $3.16 \pm 0.78$  and  $1.41 \pm 0.61$  in TRPV1<sup>+/+</sup> and TRPV1<sup>-/-</sup> animals, respectively. Composite arthritis score calculated by adding the values for all these four parameters was significantly smaller in TRPV1<sup>-/-</sup> mice ( $4.6 \pm 1.2$ , n=8) than in TRPV1<sup>+/+</sup> animals ( $7.8 \pm 1.1$ , n=8) (Figure 6).

#### **Effect of desArgHOE-140, HOE-140, indomethacin and NDGA on paw oedema, mechanical hyperalgesia and arthritic histological changes in TRPV1<sup>+/+</sup> mice**

In TRPV1<sup>+/+</sup> mice daily i.p. administration of the bradykinin B1 receptor antagonist desArgHOE-140 (250 µg/kg) did not influence significantly either CFA-induced paw swelling or mechanical hyperalgesia and had no action on the composite arthritis score. On the other hand, the B2 receptor antagonist HOE-140 (250 µg/kg) induced 30-40% inhibition of oedema and hyperalgesia throughout the whole experimental period of 18 days and decreased histological score by 55%. The non-selective lipoxygenase enzyme inhibitor NDGA (25 mg/kg) caused 40-50% inhibition of inflammatory hyperalgesia and the cyclooxygenase enzyme inhibitor indomethacin (1 mg/kg) elicited even greater, 60-80% inhibitory action. These agents decreased oedema by 25-30% and 40-55% and arthritis score by 40% and 65%, respectively (p<0.05, two-way ANOVA; Figure 4a, b, 6).

JPET#82487

## **Effect of HOE-140, indomethacin and NDGA on paw oedema, mechanical hyperalgesia and arthritic histological changes in TRPV1<sup>-/-</sup> mice**

In TRPV1<sup>-/-</sup> mice NDGA had no effect on any of the CFA-induced inflammatory symptoms. Inhibition of paw oedema induced by HOE-140 was only significant on the 18<sup>th</sup> day (19.76%), while it exerted no significant action on mechanical hyperalgesia. These drugs didn't change notably the arthritis score either. Indomethacin decreased hyperalgesia by 50-60%, oedema by 20-30% and arthritis score by 40%, respectively ( $p < 0.05$ , two-way ANOVA; Figure 5a, b, 6). It is worthy to mention, that in contrast to TRPV1<sup>+/+</sup> animals indomethacin in TRPV1<sup>-/-</sup> mice did not decrease oedema formation in the early stage of CFA-induced arthritis. The first significant inhibition, 30.07%, was detected on the 11<sup>th</sup> day and on the second and third weeks the inhibitory effect of indomethacin on paw swelling in TRPV1<sup>-/-</sup> mice was about half of the action observed in TRPV1<sup>+/+</sup> animals. On the contrary, in both groups of mice mechanical hyperalgesia was similarly diminished by indomethacin throughout the whole experimental period, although the percentage inhibition values were always higher in TRPV1<sup>+/+</sup> mice.

## **Discussion**

The present data revealed that adjuvant-induced arthritis originally developed in Lewis rats (Helyes et al., 2004) can be adapted to mice. The other commonly used experimental model, the collagen-induced arthritis, which can be used in CD1 or BALB/c mice, does not work in the C57BL/6 strain due to different responsiveness of these animals for the antigen challenge (Lariviere et al., 2001). Since transgenic mice are usually constructed from the C57BL/6 strain, this is a suitable experimental model for the examination of long-term joint inflammation in genetically manipulated animals. The significance of this technique in studying chronic

JPET#82487

inflammation in gene-deficient mice can be emphasized by the fact that the presently available data on TRPV1 knockout animals were obtained exclusively in acute models (Caterina et al., 2000; Davis et al., 2000; Banvolgyi et al., 2004). Mustard oil-induced acute neurogenic inflammation (Banvolgyi et al., 2004), carrageenin-evoked (Davis et al., 2000) and mechanical hyperalgesia one day after the CFA injection into the hindpaw did not differ in TRPV1<sup>-/-</sup> and TRPV1<sup>+/+</sup> mice (Caterina et al., 2000). These results are supported by our findings, since we also found no significant difference between these groups 24 h after the induction of inflammation. On the other hand, as arthritis proceeded, in TRPV1 knockout mice CFA-induced oedema was significantly smaller from the 2<sup>nd</sup> day and mechanical hyperalgesia from the 5<sup>th</sup> day compared to WT animals. Therefore, it seems that TRPV1 activation plays an important role in the development of the chronic, but not the acute phase of adjuvant arthritis.

Capsaicin-sensitive peptidergic afferent fibres are sensitized in arthritis and these activated nerve endings release both pro-inflammatory (tachykinins and CGRP) and anti-inflammatory neuropeptides (somatostatin) (Szolcsanyi 1998a,b). Systemic resiniferatoxin pretreatment has been shown to increase CFA-induced paw oedema, histological changes and related inflammatory hyperalgesia in rats (Helyes et al., 2004). This pretreatment, however, does not induce a selective loss of TRPV1 cation channels, they act by damaging the whole TRPV1-expressing capsaicin-sensitive nerve ending. Thus, the present results provide the first definite evidence for the regulatory role of TRPV1 receptors in the long term inflammatory and hyperalgesic symptoms of the adjuvant arthritis model. Several mediators, like bradykinin, prostaglandins, protons, histamine, serotonin, nerve growth factor (Ferrell and Lam, 1996; Szolcsanyi et al., 1998a) and endocannabinoids (Gauldie et al., 2001; Baker and McDougall, 2004) released during arthritis have been shown to activate or sensitize the capsaicin-sensitive nerve endings. TRPV1 activation induces the release of inflammatory neuropeptides like

JPET#82487

substance P and CGRP, which evoke local plasma protein extravasation, arteriolar vasodilatation (Lam and Ferrell, 1991; 1993) and stimulate inflammatory cells in the joint. These peptides have also been shown to evoke cytokine secretion from Th0, Th1 and Th2 antigen-specific T-cells (Levite and Chowers, 2001), enhance TNF- $\alpha$  production of monocytes, induce generation of IL-1 in macrophages (Brunelleschi et al., 1998), potentiate the proliferation, enzyme secretion and adhesion molecule expression of fibroblast-like synoviocytes (Lambert et al., 1998). Therefore, it is suggested that leukocytes and fibroblasts/ synovial cells are at the interface between the immune and the nervous system during long term inflammation (Lambert et al., 1998). On the other hand, other neuropeptides, like somatostatin (Helyes et al., 2004) or endomorphin-1 (McDougall et al., 2004) have been found to be anti-inflammatory in the joint.

The lipoxygenase inhibitor NDGA markedly diminished paw oedema, hyperalgesia and histological damage in TRPV1<sup>+/+</sup> mice, but had no effect in TRPV1<sup>-/-</sup> animals. It suggests that lipoxygenase products, for e.g. 12-(S)-HPETE synthesised in great amount in the inflamed tissues activate TRPV1. They bind to the same site as capsaicin located in the cytosolic domain of the receptor and on this ground it has been suggested that this lipid might be the endogenous ligand for TRPV1 (Hwang et al., 2000).

Bradykinin, a nonapeptide released in the inflamed tissues, causes pain and hyperalgesia. It is known to activate, as well as sensitize sensory neurons to other stimuli (Shin et al., 2002). We found the bradykinin B1 receptor antagonist desArgHOE-140 was ineffective in TRPV1<sup>+/+</sup> mice in the CFA-induced arthritis model. On the other hand, the B2 receptor antagonist HOE-140 induced significant inhibitory action in TRPV1<sup>+/+</sup> animals, but not in the knockouts. Upregulation of B2 receptors in joint diseases has been suggested by immunolocalization studies (Cassim et al., 1997). There are data demonstrating that this receptor subtype plays role in the sensitization of nociceptors through the protein kinase C pathway, which regulates the sensitivity of TRPV1

JPET#82487

(Sugiura et al., 2002). Furthermore, bradykinin via B2 receptors also activates TRPV1 by generating lipoxygenase products (Hwang et al., 2000). Several results suggest that lipoxygenase products are involved in the bradykinin-induced biological effects (Hwang et al., 2000).

The cyclooxygenase enzyme inhibitor indomethacin significantly diminished arthritis and related hyperalgesia in both TRPV1<sup>+/+</sup> and TRPV1<sup>-/-</sup> mice, but the percentage inhibition values compared to the respective solvent-treated control groups were smaller in the TRPV1 receptor gene deficient animals. Large body of literature describes the role of prostaglandins in inflammation (Sabata et al., 1986) and increased production of prostaglandins and thromboxane A<sub>2</sub> was found in the synovial fluid of arthritic experimental animals (Sabata et al., 1986) and patients (Basu et al., 2001), which was inhibited by indomethacin. Non-steroidal anti-inflammatory agents exert direct inhibitory actions on vasodilatation, plasma protein extravasation, leukocyte functions and also Th1 and to a lesser extent Th2 immune responses (Yamaki et al., 2003). On the other hand, prostaglandin E<sub>2</sub> and I<sub>2</sub> have been reported to act directly on capsaicin-sensitive nociceptors with cAMP as a second messenger to sensitize them to noxious stimulation (Hingtgen and Vasko, 1994). Furthermore, high concentrations of prostanoids directly evoke substance P and CGRP release from these neurons (Hingtgen and Vasko, 1994). These data can explain the greater inhibitory action of indomethacin in TRPV1<sup>+/+</sup> animals. The present results support the conclusion that TRPV1 on capsaicin-sensitive nerve endings play an important role in the mediation of prostanoids in CFA-induced arthritis, particularly in its early stage, while the prostanoid-induced hyperalgesia is only slightly affected by sensitization of the TRPV1 receptors.

There is strong evidence that not only the sensitivity, but also the density of the expression of TRPV1 is enhanced during inflammatory conditions. The proportion of TRPV1-labeled unmyelinated axons in the digital nerve significantly increases following CFA-induced

JPET#82487

chronic inflammation in the rat (Carlton and Coggeshall, 2001). These results raise the possibility that upregulation of TRPV1 at the peripheral nerve terminals is involved in the increased sensitivity of this receptor to several stimuli.

It has previously been suggested that C-polymodal nociceptors and the TRPV1 membrane protein localized on these nerve endings are integrators of noxious chemical stimuli to signal pain under inflammatory conditions (Szolcsanyi, 1993; Tominaga et al., 1998). In the present study we provided evidence that activation/sensitization of the TRPV1 receptor by lipoxygenase products, bradykinin and prostaglandins („inflammatory mixture”) enhances adjuvant-induced arthritis and related hyperalgesia in the mouse. Furthermore, while bradykinin and lipoxygenase products seem to act exclusively via TRPV1 activation, prostanoids do not, or at least partially. Based on these findings, TRPV1 channel blocking agents, endogenous ligand antagonists or their release inhibitors as lipoxygenase blocking agents, all could effectively inhibit inflammatory processes and hyperalgesia. Therefore, they might provide promising novel perspectives on drug development for the treatment of arthritis and other inflammatory diseases.

## Acknowledgements

We acknowledge Dr. J.B. Davis, GlaxoSmithKline, R&D Ltd. U.K. for the generous gift of TRPV1 knockout mice. The authors thank Mrs. Csilla Zádor and Mrs. Mária Zsoldos for their expert technical assistance in the behavioural experiments and Mrs. Anikó Perkecz for the histological slides.

## References

- Baker CL and McDougall JJ (2004) The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not in cannabinoid receptors in rat joints. *Br.J.Pharmacol.* **142**:1361-1367.
- Banvolgyi A, Pozsgai G, Brain SD, Helyes ZS, Szolcsanyi J, Ghosh M, Meleg B, and Pinter E (2004) Mustard oil induces a transient receptor potential vanilloid 1 receptor-independent neurogenic inflammation and a non-neurogenic cellular inflammatory component in mice. *Neuroscience* **125**:449-459.
- Basu S, Whiteman M, Matthey DL, and Halliwell B (2001) Raised levels of F(2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases. *Ann.Rheum.Dis.* **60**:627-631.
- Bileviciute I, Lundeberg T, Ekblom A, and Theodorsson E (1993) Bilateral changes of substance P-, neurokinin A-, calcitonin gene- related peptide- and neuropeptide Y-like immunoreactivity in rat knee joint synovial fluid during acute monoarthritis. *Neurosci.Lett.* **153**:37-40.
- Brunelleschi S, Bordin G, Colangelo D, and Viano I (1998) Tachykinin receptors on human monocytes: their involvement in rheumatoid arthritis. *Neuropeptides* **32**:215-223.
- Carlton SM and Coggeshall RE (2001) Peripheral capsaicin receptors increase in the inflamed rat hindpaw: a possible mechanism for peripheral sensitization. *Neurosci.Lett.* **310**:53-56.
- Cassim B, Naidoo S, Ramsaroop R, and Bhoola KD (1997) Immunolocalization of bradykinin receptors on human synovial tissue. *Immunopharmacology* **36**:121-125.

JPET#82487

Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeit KR, Koltzenburg M, Basbaum AI, and Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. *Science* **288**:306-313.

Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, and Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* **389**:816-824.

Chacur M, Picolo G, Gutierrez JM, Teixeira CF, and Cury Y (2001) Pharmacological modulation of hyperalgesia induced by Bothrops asper (terciopelo) snake venom. *Toxicon* **39**:1173-1181.

Chu CJ, Huang SM, De Petrocellis L, Bisogno T, Ewing SA, Miller JD, Zipkin RE, Daddario N, Appendino G, Di M, V, and Walker JM (2003) N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. *J.Biol.Chem.* **278**:13633-13639.

Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, and Sheardown SA (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. *Nature* **405**:183-187.

Ferreira J, Campos MM, Pesquero JB, Araujo RC, Bader M, and Calixto JB (2001) Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice. *Neuropharmacology* **41**:1006-1012.

Ferrel WR and Lam FY (1996) Sensory neuropeptides in arthritis, in *Neurogenic Inflammation* (Geppetti P and Holzer P eds) pp 211-227, Boca Raton: CRC Press.

Garcia-Martinez C, Humet M, Planells-Cases R, Gomis A, Caprini M, Viana F, De La PE, Sanchez-Baeza F, Carbonell T, De Felipe C, Perez-Paya E, Belmonte C, Messeguer A, and



JPET#82487

Ferrer-Montiel A (2002) Attenuation of thermal nociception and hyperalgesia by VR1 blockers. *Proc.Natl.Acad.Sci.U.S.A* **99**:2374-2379.

Gauldie SD, McQueen DS, Pertwee R, and Chessell IP (2001) Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints. *Br.J.Pharmacol.***132**:617-621.

Gauldie SD, McQueen DS, Clarke CJ, and Chessell IP (2004) A robust model of adjuvant-induced chronic unilateral arthritis in two mouse strains. *J.Neurosci.Methods* **139**:281-291.

Helyes Z, Szabo A, Nemeth J, Jakab B, Pinter E, Banvolgyi A, Kereskai L, Keri G, and Szolcsanyi J (2004) Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund's adjuvant-induced chronic arthritis model in the rat. *Arthritis Rheum.* **50**:1677-1685.

Hingtgen CM and Vasko MR (1994) Prostacyclin enhances the evoked-release of substance P and calcitonin gene-related peptide from rat sensory neurons. *Brain Res.* **655**:51-60.

Huang SM, Bisogno T, Trevisani M, Al Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, and Di M, V (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. *Proc.Natl.Acad.Sci.U.S.A* **99**:8400-8405.

Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh YG, Kim D, and Oh U (2000) Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. *Proc.Natl.Acad.Sci.U.S.A* **97**:6155-6160.

Jorgensen C and Sany J (1994) Modulation of the immune response by the neuro-endocrine axis in rheumatoid arthritis. *Clin.Exp.Rheumatol.* **12**:435-441.

JPET#82487

Lam FY and Ferrell WR (1991) Specific neurokinin receptors mediate plasma extravasation in the rat knee joint. *Br.J.Pharmacol.* **103**:1263-1267.

Lam FY and Ferrell WR (1993) Effects of interactions of naturally-occurring neuropeptides on blood flow in the rat knee joint. *Br.J.Pharmacol.* **108**:694-699.

Lambert N, Lescoulie PL, Yassine-Diab B, Enault G, Mazieres B, De Preval C, and Cantagrel A (1998) Substance P enhances cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) expression on cultured rheumatoid fibroblast-like synoviocytes. *Clin.Exp.Immunol.* **113**:269-275.

Lariviere WR, Chesler EJ, and Mogil JS (2001) Transgenic studies of pain and analgesia: mutation or background genotype? *J.Pharmacol.Exp.Ther.* **297**:467-473.

Levite M and Chowes Y (2001) Nerve-driven immunity: neuropeptides regulate cytokine secretion of T cells and intestinal epithelial cells in a direct, powerful and contextual manner. *Ann.Oncol.* **12 Suppl 2**:S19-S25.

Maggi CA (1995) Tachykinins and calcitonin gene-related peptide (CGRP) as co- transmitters released from peripheral endings of sensory nerves. *Prog.Neurobiol.* **45**:1-98.

Marabini S, Matucci-Cerinic M, Geppetti P, Del Bianco E, Marchesoni A, Tosi S, Cagnoni M, and Partsch G (1991) Substance P and somatostatin levels in rheumatoid arthritis, osteoarthritis, and psoriatic arthritis synovial fluid. *Ann.N.Y.Acad.Sci.* **632**:435-436.

McDougall JJ, Baker CL, and Hermann PM (2004) Attenuation of knee joint inflammation by peripherally administered endomorphin-1. *J.Mol.Neurosci.* **22**:125-137.

JPET#82487

Sabata S, Moshonov S, Zor U, Floman Y, and Naor Z (1986) Lipoxygenase inhibitor and colchicine as anti-arthritic agents in the rat. *Prostaglandins Leukot.Med.* **23**:95-102.

Shin J, Cho H, Hwang SW, Jung J, Shin CY, Lee SY, Kim SH, Lee MG, Choi YH, Kim J, Haber NA, Reichling DB, Khasar S, Levine JD, and Oh U (2002) Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. *Proc.Natl.Acad.Sci.U.S.A* **99**:10150-10155.

Sugiura T, Tominaga M, Katsuya H, and Mizumura K (2002) Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. *J.Neurophysiol.* **88**:544-548.

Szolcsanyi J (1993) Actions of capsaicin on sensory receptors, in *Capsaicin in the study of pain* (Wood J ed) pp 1-26, Acad. Press, London.

Szolcsanyi J (1996) Capsaicin-sensitive sensory nerve terminals with local and systemic efferent functions: facts and scopes of an unorthodox neuroregulatory mechanism. *Prog.Brain Res.* **113**:343-359.

Szolcsanyi J, Helyes Z, Oroszi G, Nemeth J, and Pinter E (1998a) Release of somatostatin and its role in the mediation of the anti-inflammatory effect induced by antidromic stimulation of sensory fibres of rat sciatic nerve. *Br.J.Pharmacol.* **123**:936-942.

Szolcsanyi J, Pinter E, Helyes Z, Oroszi G, and Nemeth J (1998b) Systemic anti-inflammatory effect induced by counter-irritation through a local release of somatostatin from nociceptors. *Br.J.Pharmacol.* **125**:916-922.

Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, and Julius D (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli. *Neuron* **21**:531-543.

JPET#82487

Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henk S, Breipohl G, König W, Knolle J, and . (1991) Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. *Br.J.Pharmacol.* **102**:774-777.

Yamaki K, Uchida H, Harada Y, Yanagisawa R, Takano H, Hayashi H, Mori Y, and Yoshino S (2003) Effect of the nonsteroidal anti-inflammatory drug indomethacin on Th1 and Th2 immune responses in mice. *J.Pharm.Sci.* **92**:1723-1729.

JPET#82487

## Footnotes:

Á. Szabó and Zs. Helyes contributed equally to the present work.

This work was sponsored by Hungarian Grants: OTKA T-034911, T-043467, TS 040753, NRDP 1A/0021/2002, ETT-03543/2003, ETT-03597/2003, ETT-05598/2003, the Hungarian Academy of Sciences and the Wellcome Trust International Research Development Award.

Zsuzsanna Helyes and Erika Pintér were supported by János Bolyai Postdoctoral Fellowships, József Németh by István Széchenyi Research Fellowship.

**Reprint requests: J. Szolcsanyi MD, PhD, DSc., Pecs-7624 Szigeti u. 12.**

## Legends for Figures

**Figure 1** Paw oedema of TRPV1<sup>+/+</sup> (wild-type, WT) and TRPV1<sup>-/-</sup> (knockout, KO) mice induced by complete Freund's adjuvant (CFA) injection throughout the 18-day experimental period. Results are expressed as percentage swelling compared to the initial paw volumes and shown as means±s.e.m. of n=12-15 mice/ group. ANOVA followed by Bonferroni's modified t-test was used to determine statistically significant differences, \*p<0.05; \*\*p<0.01 WT vs. KO.

**Figure 2** Mechanical hyperalgesia of the paw of TRPV1<sup>+/+</sup> (wild-type, WT) and TRPV1<sup>-/-</sup> (knockout, KO) mice induced by complete Freund's adjuvant (CFA) injection throughout the 18-day experimental period. Results are expressed as percentage change of touch sensitivity compared to the initial paw values and shown as means±s.e.m. of n=12-15 mice/ group. ANOVA followed by Bonferroni's modified t-test was used to determine statistically significant differences, \*p<0.05; \*\*p<0.01 WT vs. KO.

**Figure 3** Histological samples of the left tibiotarsal joints stained with hematoxylin and eosin taken from (a) an untreated TRPV1<sup>+/+</sup> (wild-type, WT), (b) an untreated TRPV1<sup>-/-</sup> (knockout, KO) mouse, (c) a complete Freund's adjuvant (CFA)-treated WT mouse and (d) a CFA-injected TRPV1<sup>-/-</sup> mouse. Magnification is 40 x in all micrographs. Syn: synovial tissue; C: cartilage; the tibia and the tarsus are indicated accordingly. Note that in the joint of the TRPV1<sup>+/+</sup> mouse the articular cavity is markedly larger, the extensively expanding synovial pannus is more densely infiltrated with mononuclear cells, cartilage erosion is more pronounced and there is a massive bone destruction by the invading synovium.

JPET#82487

**Figure 4** Effect of daily administration of the bradykinin B1 receptor antagonist desArgHOE-140 (250 µg/kg), the B2 antagonist HOE-140 (250 µg/kg), the cyclooxygenase enzyme inhibitor indomethacine (INDO, 1 mg/kg) and the lipoxygenase enzyme inhibitor nordihydroguaretic acid (NDGA, 25 mg/kg) on CFA-induced (a) paw oedema and (b) mechanical hyperalgesia in TRPV1<sup>+/+</sup> (wild-type, WT) mice. Results are means±s.e.m. of n=6-8 mice/ group. ANOVA followed by Bonferroni's modified t-test was used to determine statistically significant differences, \*p<0.05; \*\*p<0.01 vs. solvent-treated control group.

**Figure 5** Effect of daily administration of the bradykinin B1 receptor antagonist desArgHOE-140, the B2 antagonist HOE-140, the cyclooxygenase enzyme inhibitor indomethacine (INDO) and the lipoxygenase enzyme inhibitor nordihydroguaretic acid (NDGA) on CFA-induced (a) paw oedema and (b) mechanical hyperalgesia in TRPV1 gene deficient (KO) mice. Results are means±s.e.m. of n=6-8 mice/ group. ANOVA followed by Bonferroni's modified t-test was used to determine statistically significant differences, \*p<0.05; \*\*p<0.01 vs. solvent-treated control group.

**Figure 6** Histological scores. Arthritic changes like inflammatory cell infiltration, synovial proliferation/ enlargement, articular cartilage breakdown and bone destruction were graded from 0 to 3 and added. Results are means±s.e.m. of n=6-8 samples/ group. Non-parametric Mann-Whitey U-test was used to determine statistically significant differences, \*p<0.05; \*\*p<0.01.

Fig.1.











Fig.2.










# Fig.4.



# Fig.5.





Fig.6.

